Floatz logo

Apl-5125

Endometrial Adenocarcinoma

Apollo Therapeutics LtdPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

11 Active assets in the Endometrial Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Carboplatin
Daniela Matei, MD
Phase 2BB
Olaparib
National Cancer Institute (NCI)
Phase 2B
Capivasertib
National Cancer Institute (NCI)
Phase 2B
Cediranib
National Cancer Institute (NCI)
Phase 2B
Metformin
University of Arkansas
Phase 2B

View all 22 →

Same molecule, other indications

Apl-5125 is also rated in:

appendix adenocarcinomaDormant
CCC
Indicative ·
48 / 100
View asset →
cholangiocarcinomaDormant
CC
Indicative ·
43 / 100
View asset →
pancreatic adenocarcinomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →